Jenburkt Pharma
BSE: JENBURPH · Pharmaceuticals
Snapshot
Unlock Jenburkt Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jenburkt Pharmaceuticals Ltd. is an Indian pharmaceutical company engaged in the manufacturing and marketing of diverse healthcare formulations. Its product portfolio spans therapeutic areas including anti-arthritic, anti-osteoporotic, antibiotic, and dermatological treatments.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations across domestic and international markets. It operates as a manufacturer and marketer of branded healthcare products.
Growth Outlook
Growth is driven by the expansion of its therapeutic product range and the strengthening of its presence in both local and export markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and regulatory approvals from health authorities in India and export destinations.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins for pharmaceutical manufacturers.
- Market Competition. The highly fragmented Indian pharmaceutical sector exposes the company to intense price competition from both large multinationals and domestic generic players.
- Supply Chain Volatility. Fluctuations in the cost and availability of Active Pharmaceutical Ingredients (APIs) can disrupt production schedules and affect operating costs.
Price
Start your research today
Unlock AI insights, financials, peers and live data on Jenburkt Pharma and 5,000+ companies — free.
Key Metrics
P/E
13.8x
Q4 FY26 · standalone
EV/EBITDA
8.8x
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap (Cr) | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Jenburkt PharmaJENBURPH | 451 | 13.84 | 8.79 | — | 32.0% | 17.6% | 23.2% | -15.6% |
KopranKOPRAN | 561 | 38.27 | 18.22 | 8.2% | 9.1% | 4.9% | 7.7% | +12.4% |
Influx Health.INFLUX | 508 | — | — | — | 20.0% | — | — | +79.7% |
Haleos Labs LimitedHALEOSLABS | 380 | 27.58 | 12.42 | -3.2% | 14.1% | 8.9% | 12.2% | — |
Amanta HealthcarAMANTA | 377 | 36.48 | 8.39 | — | 22.0% | 6.8% | 10.0% | — |
Albert DavidALBERTDAVD | 371 | -263.95 | 32.85 | -3.5% | 3.9% | -0.4% | 0.8% | -24.9% |
As of Q4 FY26
Financials
Jenburkt Pharma
BSE: JENBURPH · Pharmaceuticals
Snapshot
Unlock Jenburkt Pharma's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Jenburkt Pharmaceuticals Ltd. is an Indian pharmaceutical company engaged in the manufacturing and marketing of diverse healthcare formulations. Its product portfolio spans therapeutic areas including anti-arthritic, anti-osteoporotic, antibiotic, and dermatological treatments.
Business Model
The company generates revenue through the production and sale of pharmaceutical formulations across domestic and international markets. It operates as a manufacturer and marketer of branded healthcare products.
Growth Outlook
Growth is driven by the expansion of its therapeutic product range and the strengthening of its presence in both local and export markets.
Key Risks
- Regulatory Compliance. The company faces risks related to stringent quality standards and regulatory approvals from health authorities in India and export destinations.
- Price Controls. Government-mandated price caps on essential medicines in India can significantly impact profit margins for pharmaceutical manufacturers.
- Market Competition. The highly fragmented Indian pharmaceutical sector exposes the company to intense price competition from both large multinationals and domestic generic players.
- Supply Chain Volatility. Fluctuations in the cost and availability of Active Pharmaceutical Ingredients (APIs) can disrupt production schedules and affect operating costs.
Price
Loading…
Start your research today
Unlock AI insights, financials, peers and live data on Jenburkt Pharma and 5,000+ companies — free.
Key Metrics
P/E
13.8x
Q4 FY26 · standalone
EV/EBITDA
8.8x
Q4 FY26 · standalone
DEBT TO EQUITY
0.0x
Q4 FY26 · standalone
Peers · Pharmaceuticals
As of Q4 FY26